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Abstract
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Among the EGFRs, HER2 is a major heterodimer partner and also has important implications in
the formation of particular tumors. Interaction of HER2 protein with other EGFR proteins can be
modulated by small molecule ligands and, hence, these protein-protein interactions play a key role
in biochemical reactions related to control of cell growth. A peptidomimetic (compound 5-1) that
binds to HER2 protein extracellular domain and inhibits protein-protein interactions of EGFRs
was conjugated with BODIPY (4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene).
Conjugation of BODIPY to the peptidomimetic was investigated by different approaches. The
conjugate was characterized for its ability to bind to HER2 overexpressing SKBR-3 and BT-474
cells. Furthermore, cellular uptake of conjugate of BODIPY was studied in the presence of
membrane tracker and Lyso tracker using confocal microscopy. Our results suggested that
fluorescently labeled compound 5-7 binds to the extracellular domain and stays in the membrane
for nearly 24 h. After 24 h there is an indication of internalization of the conjugate. Inhibition of
protein-protein interaction and downstream signaling effect of compound 5-1 was also studied by
proximity ligation assay and western blot analysis. Results suggested that compound 5-1 inhibits
protein-protein interactions of HER2-HER3 and phosphorylation of HER2 in a time-dependent
manner.
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Human epidermal growth factor receptors (EGFRs) are important molecules in signal
transduction processes in cells and provide the signal for cell growth, differentiation, and
motility. There are four well known EGFRs, namely, EGFR/HER1/ERBB1, HER2/ERBB2,
HER3/ERBB3, and HER4/ERBB4. HER1 and HER2 have been associated with various
cancers through their overexpression on the cell surfaces of tumors [1–3]. Each receptor
exists as a monomer, consisting of an extracellular domain (containing four domains (I–
IV)), a transmembrane domain, a cytosolic tyrosine-kinase-containing domain, and the
regulatory domain, through which cell signaling to the nucleus occurs [3–7]. EGFRs interact
with one another upon ligand binding to their extracellular domains, and form homo- and
heterodimers [3, 8, 9]. Formation of these heterodimers is important in generating signals for
cell growth and differentiation. Other possible dimers such as EGFR-HER2, HER2-HER3,
and HER2-HER4 have been proposed in the literature [10]. Blockade of protein-protein
interactions (PPI) of the extracellular domains of EGFRs ultimately leads to control of cell
growth [11–14]. Among the EGFRs, HER2 is a major heterodimer partner and also has
important implications in the formation of particular tumors. Interaction of HER2 protein
with other EGFR proteins can be modulated by small molecule ligands and, hence, these
protein-protein interactions play a key role in biochemical reactions related to control of cell
growth [13, 15–18]. Antibodies and affibody molecules targeting HER2 protein are
investigated as probes or as imaging agents with radioactive probes, quantum dots, and
fluorescent probes [19, 20]. Peptides designed to target the extracellular domain (ECD) of
HER2 have been reported to interfere with the dimer interface of HER2 with EGFR [21–23].
Other small molecules have been reported to interfere with the EGFR extracellular domain
[24]. These molecules were designed for therapeutic or imaging purposes. Some of these
molecules bind to HER2 protein with high affinity, but do not interfere with PPI [23]. Our
approach is to use peptidomimetics and their conjugates to study hot spots in PPI in the ECD
of EGFRs. Among the ECD of EGFRs, domain II is well characterized. Domain IV is close
to the membrane environment and dynamic in nature; it is not well characterized because in
the crystal structure the electron density of domain IV is not well defined [25, 26]. Domains
IV of HER2 and EGFR are known to interact with each other. Thus, we chose to study
domain IV PPI interaction. In our preliminary study, we have shown that a peptidomimetic,
namely, compound 5-1 (Scheme 1), modulates dimerization of EGFR-HER2/HER2-HER3
[27–30]. This work focuses on conjugation of the fluorescent probe 4,4-difluoro-5,7dimethyl-4-bora-3a,4a-diaza-s-indacene (BODIPY) to compound 5-1 to modulate PPI
interactions of EGFRs [31–34]. Furthermore, we characterized the binding and cellular
uptake of BODIPY conjugate of 5-1 (compound 5-7) in HER2-overexpressing breast cancer
cell lines. Inhibition of protein-protein interaction of the compound 5-1 was also studied by
proximity ligation assay (PLA). Our results suggested that fluorescently labeled compound
5-7 binds to the extracellular domain and stays in the membrane for nearly 24 h. After 24 h
there is an indication of internalization of the conjugate.
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2. Results
2.1 Synthesis of BODIPY-compound 5-1 conjugates
The synthesis of BODIPY-compound 5-1 conjugate was performed using two methods: 1)
solution-phase conjugation of peptomimetics 5-1 and 5-2 to 5-3 (Scheme 1) and 2) solidphase conjugation using 5-6 (Scheme 2).
The direct conjugation of peptidomimetic 5-1 to commercially available compound 5-3
under basic conditions (Et3N) gave low yields of conjugate due to the competing
polymerization reaction of peptomimetic 5-1. Therefore, a tert-butyl protecting group was
introduced at the C-terminus of 5-1, which is stable under the basic conditions needed for
Eur J Med Chem. Author manuscript; available in PMC 2014 July 01.
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conjugation. The tert-butyl ester can be formed by several methods, including strong acidic
conditions. Mechanistically, the reaction is acid catalyzed with sulfuric acid, then tertiary
butanol is added to complete the esterification. To prevent water from forming and causing
hydrolysis of the ester, anhydrous magnesium sulfate was added. Compound 5-2 was
obtained in 54% yield. Solution-phase conjugation of 5-2 to compound 5-3 in DMF for 72 h
gave 20% of tert-butyl protected compound 5-4. Due to the low overall yield of this method,
solid-phase conjugation was then investigated.
For the solid-phase conjugations, compound 5-1 was prepared by SPPS on two different
resins, the Rink amide resin and the Wang resin. The Rink amide resin provided the final
conjugate with a C-terminal amide functionality whereas the Wang resin gave product 5-7
with a carboxyl group at the C-terminal (similar to active compound 5-1) that was used in
the biological studies. Conjugation of BODIPY 5-3 to compound 5-6 in Et3N and DMF
proceeded for a total of 72 h. The progress of the reaction was monitored by mass
spectrometry. Once the mass of the conjugation was confirmed, the entire conjugate was
cleaved from the resin using cleavage cocktail, dried, and washed with cold ether to remove
scavangers. Conjugation of 5-3 to compound 5-6 in Et3N and DMF gave the target
conjugate 5-7 in 45% yield after purification by preparative TLC (10% MeOH/90% DCM)
(Fig. 1)
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2.2 PLA assay to study protein-protein interaction and its inhibition by compound 5-1
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Any protein-protein interaction can be detected by PLA probes if the two proteins are in
proximity of less than 16 nm [35]. One of our objectives is to design compounds to inhibit
protein-protein interactions of EGFRs, in particular, EGFR-HER2 and HER2-HER3. PLA
assay is used to study protein-protein interactions in native cellular environment [35, 36],
and thus can be used to study HER2-HER3 interaction and its disruption by compound 5-1.
This method provides direct evidence of modulation of HER2-HER3 interaction by peptides
we have designed. PLA is an antibody-based method in which two proteins (or antigens) are
immunolabeled first with two primary antibodies and then with different species-specific
secondary antibodies conjugated to complementary oligonucleotides [36]. When two
antibody molecules are in close proximity (<16 nm), the complementary DNA strands can
be ligated, amplified, and visualized with a fluorescent probe as distinct fluorescent spots.
Each fluorescent spot corresponds to a heterodimer on a breast cancer cell. Using PLA, we
could observe HER2-HER3 heterodimers in SKBR3 cells by the probes, seen as red spots. If
compound 5-1 inhibits HER2 heterodimerization, there should be no red spots or relatively
fewer spots compared to the control. SKBR-3 cells were treated with compounds 5-1 and a
control peptide for 24 h. Confocal images of the cells without any compound 5-1 treatment
clearly show many HER2-HER3 heterodimers on SKBR-3 cells (Fig. 2A). Treatment with a
control peptide did not inhibit HER2-HER3 heterodimers (Fig. 2B). A sub-optimum dose of
compound 5-1 did not inhibit HER2-HER3 heterodimerization to a significant extent (Fig.
2C) whereas optimum doses of compound 5-1 at 0.8 μM inhibited HER2-HER3
heterodimerization significantly (Fig. 2D). This clearly suggests that compound 5-1
designed is a potent inhibitor of HER2 heterodimerization with HER3.
2.3 Time-dependent inhibition of phosphorylation of HER2 kinase
HER2 heterodimerization causes transphosphorylation and activation of the downstream
signaling cascade, resulting in cell growth and proliferation [3, 5, 37]. Thus, inhibiting
phosphorylation of HER2-mediated dimers plays a major role in inhibiting cell growth and
proliferation. To evaluate the effect of compound 5-1 on the dimerization of full-length
EGFRs in the native form in HER2-overexpressing breast cancer cell lines, the effect of
compound 5-1 on the phosphorylation of HER2 kinase domain in BT-474, SKBR-3 and
MCF-7 cells was investigated using Western blot. Inhibition of the receptor
Eur J Med Chem. Author manuscript; available in PMC 2014 July 01.
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heterodimerization or association in cells by compound 5-1 should decrease the
phosphorylation level of HER2 protein. Phosphorylation was detected using p-HER2, an
antibody that specifically binds to the phosphorylated HER2 protein. Fig. 3 represents the
Western blot analysis of the phosphorylation level in treated and untreated BT-474 and
SKBR3 cells, respectively. Cells without compound 5-1 and AG-825 (0.38 μM, a kinase
inhibitor, not shown) [37, 38] were used as a control. Comparison of the inhibition of
phosphorylation and control suggested that compound 5-1 showed significant inhibition of
phosphorylation of HER2 in BT-474 and SKBR-3 cells in a time-dependent manner. A
significant inhibition of HER2 phosphorylation was observed after 18 h of treatment with
compound 5-1. These results clearly suggest that binding of compound 5-1 to ECD affects
the intracellular transphosphorylation and, hence, the signaling process. MCF-7 cells that do
not show overexpression of HER2 protein were used as a control, and no phosphorylation of
HER2 was detected in those cells.
2.4 Cellular binding and uptake studies
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Compound 5-1 has been shown to bind to the HER2 extracellular domain on BT-474 and
SKBR-3 cells that overexpress HER2 protein. Once compound 5-1 binds, inhibition of
EGFR-HER2 and HER2-HER3 dimerization takes place and, hence, disrupts the
phosphorylation. However, the fate of compound 5-1 after the inhibition of PPI of EGFRs is
not known. In our earlier report we have shown that compound 5-1 with free carboxy
terminal exhibits antiproliferative activity against HER2 overexpressing breast cancer cells
[27]. Thus, we investigated the cellular binding and uptake of compound 5-1 by conjugating
it with BODIPY (compound 5-7). Time-dependent uptake was monitored by fluorescence
emitted from the SKBR-3 cells at two different concentrations of compound 5-7 (1 and 10
μM). At 1 μM concentration of the conjugate, there was a steady increase in fluorescence
with respect to time up to 72 h. At 10 μM concentration of the conjugate, saturation was
observed after 48 h. (Fig. 4). These data correlate with the time-dependent inhibition of
HER2 phosphorylation by compound 5-1 (Fig. 3). To further investigate the importance of
the increase in fluorescence and localization of the compound 5-7, cellular uptake was
monitored by confocal microscopy using membrane and Lyso trackers. Confocal images
suggested that, even after 24 h, the majority of compound 5-7 is on the surface or membrane
of SKBR-3 cells (Fig. 5). Images of cells after 48 h of compound 5-7 incubation using Lyso
tracker marker show clearly that part of the conjugate is taken up into the cell as indicated in
Fig. 6. These data suggest that the compound 5-7 binds to the extracellular domain of HER2
protein on the surface of SKBR-3 cells and possibly is internalized after 48 h. The exact
mechanism of internalization is not clear at this stage.
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3. Discussion
HER2, also known as ERBB2, is found to overexpress in many epithelial malignancies. It is
well established that HER2-mediated heterodimerization plays key roles in the progression
of such cancers [1–10, 17]. It has been reported that EGFR-HER2 and HER2-HER3
heterodimers are major contributors to mediating the pathological effects of this
overexpression in HER2-overexpressing breast cancer [9, 10, 17]. Inhibition of HER2
heterodimerization contributes significantly to the treatment of HER2-positive breast
cancers. Compound 5-1 that we have designed has been shown to bind to the HER2
extracellular domain and inhibit protein-protein interactions. Conjugation of compound 5-1
to BODIPY was achieved using different synthetic strategies. Although conjugation of
fluorescent molecules seems to be quite simple using amine coupling methods, conjugation
to purified compound 5-1 posed a problem. Hence, compound 5-1 had to be conjugated to
the peptide on the resin. The conjugate (compound 5-7) was characterized by mass
spectrometry and UV-fluorescence spectroscopy. Cellular uptake studies suggested that the

Eur J Med Chem. Author manuscript; available in PMC 2014 July 01.
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compound 5-7 is taken up by HER2-overexpressing cell lines in 48 h and, at a concentration
of 10 μM, saturation in the uptake was observed. At present, the exact mechanism cannot be
proposed for this observed result; multiple mechanisms could be possible for the timedependent uptake of the compound 5-7. As the binding site of compound 5-1 is HER2domain IV, which is close to the cell membrane, its conjugate, compound 5-7 might be
trapped in the cell membrane after dissociation. Finally, after exerting its action, compound
5-7 might internalize into the organelles of the breast cancer cell. To determine the
possibility of internalization, cells were incubated with the compound 5-7 for 24 and 48 h
and co-localization of compound 5-7 with membrane and Lyso trackers was observed using
confocal microscopy. The results clearly suggested that the conjugate stays on the cellular
surface up to 24 h, indicating binding to ECD of HER 2 protein. However, after 48 h, there
was an indication of internalization of the compound 5-7. EGFR receptors are known to
undergo internalization after forming ligand-bound dimers. These dimers are known to be
sorted in endosomes and recycled back to the surface and/or undergo endosomal degradation
[39–41]. Our results suggest that compound 5-7 bound to HER2 protein is retained
extracellularly for up to 24 h and, hence, may not undergo recycling with the receptor.
Previous studies have reported that overexpression of HER2 and EGFR-HER2
heterodimerization completely abolishes the EGFRs degradation process [42]. However,
recent literature suggested that HER2 overexpression and heterodimerization slows down
EGFR internalization and degradation [39–41]. Results from our studies suggested that
compound 5-7 that binds to the HER2 extracellular domain is retained extracellularly for 24
h, which correlates with a slowdown of the internalization process of EGFR heterodimers.
To show that compound 5-1 inhibits protein-protein interaction, we carried out PLA assay.
Those results clearly suggest that inhibition of dimerization of extracellular domains of
HER2 and HER3 results in inhibition of PPI of HER2-HER3. Full-length EGFRs have
several regions of contact for PPI when they form homo- and heterodimers [3, 5, 9]. Domain
II, the dimerization arm, domain IV, the transmembrane domain, and the kinase domain all
form contacts for PPI of EGFRs. Among these, domain II interactions are well understood in
EGFR homodimers, and the antibody pertuzumab, which binds to domain II of HER2
protein, inhibits PPI of EGFRs [14]. The interaction of domain IV is not well understood.
The literature suggests that domain IV may be involved in stabilizing the PPI of EGFRs.
However, the contribution of domain IV to PPI is very weak. Studies also suggest that
domain IV helps to align the transmembrane domains [43]. The crystal structures of
homodimers of EGFR suggest that hydrophobic residues such as Leu582, Trp584, and
Tyr602 participate in PPI of domain IV to stabilize the interaction of homodimers of EGFR
near the transmembrane [26]. The results from our current and previous studies [28, 30]
clearly suggest that a peptidomimetic that we designed targets domain IV and inhibits PPI in
vitro as seen in the PLA assay. This inhibition in turn has the pharmacological action of
inhibition of phosphorylation of the kinase domain and, hence, modulation of the signal for
cell growth. Furthermore, inhibition of the extracellular domain of HER2-HER3 inhibits the
phosphorylation of HER2 protein in a time-dependent manner. Western blot analysis of
HER2 phosphorylation showed maximum inhibition of HER2 phosphorylation after 24 h of
treatment. We have also shown that conjugation of a peptidomimetic that binds to domain
IV of HER2 with a fluorescent label such as BODIPY helps us to study the molecular
mechanism of the signal transduction process. These studies taken together suggest that a
compound 5-7 could be used as a tool to study the binding and internalization of EGFR
receptors and their heterodimerization. The data presented here provide a new tool to study
the EGFRs PPI inhibition and EGFR trafficking.

4. Conclusions
A peptidomimetic (compound 5-1) that binds to HER2 protein extracellular domain and
inhibits protein-protein interactions of EGFRs was conjugated with the fluorescent dye
Eur J Med Chem. Author manuscript; available in PMC 2014 July 01.
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BODIPY. Synthesis was achieved with conjugation on solid-phase synthesis. PPI inhibition
activity of the compound was evaluated by proximity ligation assay. The PLA assay
suggested that the compound inhibits HER2-HER3 heterodimerization in lower micromolar
concentrations effectively. The downstream signaling effect of PPI inhibition was evaluated
by time-dependent phosphorylation by compound 5-1. Compound 5-1 inhibited
phosphorylation significantly within 18 to 24 h. To evaluate the effect of compound on the
PPI of EGFR and the fate of the compound after PPI inhibition, cellular uptake of the newly
synthesized BODIPY conjugate of compound 5-1 (compound 5-7) was studied by
fluorescence plate reader assay and confocal microscopy with organelle tracers. Compound
5-7 seems to reside in the extracellular region or in the membrane for up to 24 h; at 48 h,
there was an indication of internalization. The internalization was viewed in terms of EGFR
trafficking. However, more detailed studies of the kinetics of EGFR trafficking are
necessary to understand the receptor internalization and recycling to the surface of cells
using fluorescent conjugates. Thus, the conjugates designed here will be useful tools for
studying EGFR trafficking and the effect of inhibition of HER2 heterodimerization on
EGFR trafficking and ligand receptor interactions.

5. EXPERIMENTAL PROCEDURES
5.1 General information
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All chemicals, biochemicals and solvents were purchased from commercial sources. All
peptide synthesis reagents were purchased from Fisher Scientific or Sigma Aldrich as ACS
grade or peptide synthesis grade solvents. Amino acids were purchased from AnaSpec
(Fremont, CA) or Applied Biosystems (Carlsbad, CA). Beta-amino acid, Fmoc-3-amino-3(1-naphthyl)-propionic acid]-OH, was purchased from Chem-Impex International (Wood
Dale, IL). Analytical thin-layer chromatography (TLC) was carried out using polyester
backed TLC plates 254 (precoated, 200 μm) from Sorbent Technologies. NMR spectra were
recorded on an AV-400 LIQUID Bruker spectrometer (400 MHz for 1H). 2D TOCSY
spectra of compounds 5-1 and 5-7 were recorded in 500 and 700 MHz Varian NMR
spectrometers respectively. The chemical shifts are reported in δ ppm using the following
deuterated solvents as internal references: acetone-d6 2.05 ppm (1H), DMF-d7 8.03 ppm
(1H), H2O 90%/D2O 10%. HPLC analyses were carried out on a Dionex system equipped
with a P680 pump and UVD340U detector. MALDI-TOF mass spectra were recorded on a
Bruker ProFlex III mass spectrometer using dithranol as the matrix or Bruker
UltrafleXtreme (MALDI-TOF/TOF) using 4-chloro-α-cyanocinnamic acid as the matrix;
ESI mass spectra were obtained on an Agilent Technologies 6210 time-of-flight LC/MS
with a quaternary gradient module pump, 2489 UV-visible detector, and fraction collector
III. Analytical HPLC was carried out using a XBridge C18 300 Å, 5 μm, 4.6 mm × 250 mm
column (Waters, USA) and a stepwise gradient. Semipreparative HPLC was carried out
using a XBridge C18 300 Å, 5 μm, 10 mm × 250 mm column (Waters, USA) and a stepwise
gradient. The solvent system for peptides consisted of Millipore water and HPLC-grade
acetonitrile/methanol. Antibodies for Western blot analysis were obtained from Abcam, Inc.
(Cambridge, MA). Antibodies and wash buffers A and B for PLA were obtained from
Axxora, LLC (Farmingdale, NY) and nanoTools (San Diego, CA). Control peptide was
custom synthesized by Polypeptide laboratories (San Diego, CA).
5.2 Chemistry
5.2.1 Synthesis of compound 5-1—The peptidomimetic (compound 5-1) was
synthesized by different methods to determine the efficiency of conjugation. Conjugation of
BODIPY to compound 5-1 was attempted using different methods: 1) conjugation to
derivative compound 5-2 in solution phase (Scheme 1), 2) solid-phase conjugation using on
Wang resin and on Rink amide resin. Since biological activity of compound 5-7 sythesized
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using Wang resin was evaluated. Details of synthesis of Rink amide resin based conjugate is
provided elsewhere (Ph.D dissertation, Alecia McCall, Louisiana State University April
2012).
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Peptidomimetic compound 5-1 was synthesized by manual solid-phase synthesis using
standard procedures[44]. The peptide was synthesized on Wang resin on a 0.2 mmol scale
using the Fmoc strategy of solid-phase peptide synthesis. A four fold excess of the L-Fmocprotected amino acids was coupled using PyAOP/HOBT or HATU as the coupling and
activating agents. Resins were allowed to swell in DMF for 1 h, and the Fmoc-protecting
group was removed from the resin. For coupling Arg to the growing peptide chain, double
coupling was performed. The Fmoc-protecting group was cleaved with 93% DMF, 5%
piperidine, and 2% DBU once for 3 min, once for 5 min, and once for 10 min. This was
followed by washing the peptide several times with DMF after which the next amino acid
was coupled. The Fmoc group from phenylalanine was not cleaved until the peptide was
ready for use. The peptide was then washed with DMF (3 × 30 s) and DCM (3 × 30 s),
respectively, and dried under high vacuum for 24 h. The peptide was then cleaved using a
cleavage cocktail consisting of TFA/liquefied phenol/water/Tris (88:5:5:2) for 5 h. This
cocktail was then precipitated into anhydrous ethyl ether (−80 °C) and centrifuged. The
precipite was washed three times with anhydrous ethyl ether (−80 °C) and then dissolved in
water and acetonitrile and lyophilized. Reversed-phase HPLC analysis, mass spectrometry,
and NMR studies were performed to evaluate the purity of compound 5-1. High resolution
mass spectrum and 1H 2D NMR of compound 5-1 with assignments are provided as
supporting information.
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5.2.2 Synthesis of tert-butyl Peptomimetic (5-2)—In a small round bottom flask,
anhydrous magnesium sulfate (0.232 mg, 0.00193 mmol) in 3 mL of dry DCM was stirred
vigorously for 10 min. Excess concentrated sulfuric acid (92.00 mg, 0.9380 mmol) was
added to the flask. The mixture was stirred for 1 h. Compound 5-1 (0.25 mg, 4.82×10−4
mmol) was then added to the mixture (Scheme 1). The flask was sonicated to ensure
solubility and stirred for an additional 5 min before adding tertiary butanol (0.228 mL,
0.00241 mmol). The flask was stoppered and stirred for 24 h at 25 °C under N2 gas. The
reaction was quenched with saturated sodium bicarbonate (3 mL) by adding this to the
reaction flask until all of the magnesium sulfate had dissolved. The organic phase was
separated, washed with brine, dried with Na2SO4, and purified by preparative TLC to afford
the t-butyl protected compound (5-2) in 54% yield (0.15 mg). 1H NMR (400 MHz, acetoned6) δ ppm 1.28 (br, 9H), 1.51–1.62 (m, 2H), 1.79 (m, 2H), 3.30 (m, 2H), 4.50–4.63 (m, 1H),
5.34 ( 1H), 6.24–6.31 (m, 1H), 7.00–7.10 (m 5H), 7.15 (1H), 7.32 (1H) 7.31 (d, J=4.26 Hz
1H), 7.42–7.80 (m 7H), 7.93 (d, J=7.31 Hz 1H), 8.15 (br, 1H), 8.22 (m, 1H). Arg side chain
guanidine group protons (4H) were broad, and phenyl alanine beta protons (2H) were under
the solvent peak around 3 ppm, and hence could not be identified. MS (MALDI-TOF): m/z
597.428. Calcd. for C32H42N6O4: 597.316 [M+Na].
5.2.3 Synthesis of BODIPY succinimidyl ester tert-butyl Arg-[3-amino-3-(1napthyl)-propionic acid]-Phe (5-4) (Scheme 1)—Compound 5-3 was purchased from
Life Technologies (Carlsbad, CA). To a small round bottom flask was added 5-3 (0.826 mg,
0.00198 mmol) in peptide synthesis grade DMF (1 mL). Compound 5-3 was sonicated to
ensure solubility. Six (6) equivalents of triethylamine (1.65 μL, 0.011 mmol) were added to
the flask. Compound 5-3 was activated for 4.5 h under inert conditions (N2 gas) before
compound 5-2 (2.3 mg, 0.00198 mmol) in 0.5 mL peptide synthesis grade DMF was added
to the flask. Conjugation took place for 72 h under nitrogen. Confirmation of mass was
observed by MS (ESI-MS): m/z 820.737. Calcd. for C44H51BF2N8O5 820.734 [M-tBu].
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5.2.4 Conjugation of BODIPY 5-3 to Arg-[3-amino-3-(1-napthyl)-propionic
acid]-Phe on Wang Resin (5-7)—Synthesis of compound 5-7 (Scheme 2) was achieved
by routine solid-phase peptide synthesis. To a reaction vessel compound 5-3 (0.0021 g,
0.0050 mmol) was added and solubilized in 0.9 mL DMF. Triethylamine (0.006 mL, 0.043
mmol) was added to the vessel and stirred to activate the ester (Scheme 2). The reaction
continued for 1 h. This solution was added to the peptide synthesis chamber containing 5-6
(0.0050 g, 0.00479 mmol) (Scheme 2). The reaction proceeded with shaking for
approximately 72 h under N2. The beads were then washed with DMF 4 times until the
filtrate was colorless to remove residual compound 5-3. A cleavage cocktail consisting of 1
mL of TFA (88%), liquefied phenol (5%), triisopropylsilane (2%), and water (5%) was
added to the resin beads for 4 h. The resin was filtered and washed with TFA (3 × 1 mL).
Filtrates were combined, evaporated, and washed with cold anhydrous ether. Purification
was conducted by preparative TLC (10% MeOH/90% DCM) and analytical HPLC (ACN/
H2O) to yield 45%–65% of conjugate. 1H NMR (700 MHz, DMF-d7) δ ppm 8.75 (br, 1H),
8.14 (d, J=7.0Hz 1H), 7.99 (d, J= 7.52 1H), 7.88 (br, 1H), 7.60–7.80 (m, 4H), 7.31(br, 1H),
7.24(m, 3H), 6.80–7.00(m,6H), 6.41–6.62(br. 2H), 6.30(br, 1H), 6.00 (br, 1H), 4.45(m, 1H),
4.31 (m, 1H), 3.21–3.42(br, 6H), 2.80–2.84 (m, 3H), 2.42(m, 3H), 1.90–2.00 (m, 2H), 1.61–
1.77 (m, 3H), 1.45–1.50 (m, 3H), 1.21–1.60 (m, 6H). C-terminal carboxylic acid proton
were broad and were not observed. MS (ESI-TOF): m/z 821.408. Cald. for C44H51BF2N8O5
821.411 [M+H] (Fig. 1). UV-vis (DMSO) λmax (nm) (ε, L mol−1 cm−1): 485 nm (4.49E
+05), 351 (5.90E+05).
5.3 Proximity ligation assay
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Proximity ligation assays (PLA) were performed on breast cancer cells SKBR-3 that
overexpress HER2 protein [35, 36]. PLA assay on breast cancer cells was performed by
coating 5 × 104 cells onto each well in an 8-chambered plate. The plate was incubated for 24
h at 37 °C. Compound 5-1 was added at two different concentrations (0.5 and 0.8 μM). A
control peptide (supporting information) was also added at 1 μM concentration. After 24 h,
the medium was removed and the wells were washed 3 times with 500 μL of PBS. The cells
were fixed by adding 500 μL of ice-cold methanol for 5–8 min and incubating the plate at
−20 °C. The methanol was discarded and immediately 500 μL of PBS was added twice to
the wells to prevent cell dehydration. The cells were then blocked with 200 μL of 5% BSA
for 1 h in a humidity chamber. The blocking solution in the wells was discarded, and 200 μL
of 1:400 dilutions of primary antibodies (both HER2 (anti-rabbit) and HER3 (anti-mouse))
in 2% BSA were added to the wells. The 8-chambered well plate was then incubated at 4 °C
in a humidity chamber overnight. Primary antibodies were discarded and the plate was
washed twice with wash buffer (from PLA kit) for 5 min. To the cells, two PLA probes
(anti-mouse and anti-rabbit) at 1:5 dilution in 2% BSA were added and incubated for 1 h at
37 °C in a humidity chamber. Slides were washed with wash buffer for 5 min twice, and
ligation stock at 1:5 dilution in high purity water was added and incubated for 30 min at 37
°C. The slides were washed again with wash buffer, amplification solution was added, and
the slide was incubated for 2 h at 37 °C. Slides were then washed twice with wash buffer for
10 min. The slides were dried at room temperature, mounted with mounting medium
(Duolink II), and stored at −20 °C until confocal images were taken. Cells were viewed with
a confocal microscope (LSM 5 PASCAL). Images were taken at 40X as wells and at 60X
under oil immersion.
5.4 Time-dependent inhibition of phosphorylation of HER2 kinase
BT-474 cells were maintained in RPMI-1640 supplemented with pen-strep 1 mL/100 mL,
insulin 1 mg/100 mL, and 10% FBS. SKBR-3 cells were maintained in McCoy’s medium
supplemented with penstrep 1 mL/100 mL, insulin 1 mg/100 mL, and 10% FBS. After
confluency, cells were trypsinized and plated in T-75 flasks in triplicate. After 24 h, the cells
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were either treated with compound 5-1 (0.4 μM) or left untreated. Cells with compounds
were incubated at 37 °C and 5% CO2. After the incubation period, cells were trypsinized,
collected in 15 mL tubes, and centrifuged at 200 ×g. To the pellet, 200 μL of cell lysis
buffer containing 20 μL of protease inhibitor and 20 μL of phosphatase inhibitor was added.
Tubes were vortexed for 1 min and then kept on ice for 10 min. This process was repeated
twice. Cells were subjected to centrifugation at high speed (450 ×g) and the supernatant was
collected in separate tubes and stored at −80 °C until further use. Protein concentration in
the tubes was analyzed using Bradford’s assay. 40 μg of protein from each sample was
loaded on 10% SDS-polyacrylamide minigels. The gels were run at 30 mA, 125 V and then
transferred at 30 V for 12–16 h at 4 °C onto a nitrocellulose membrane. After transfer, the
membranes were blocked with 5% milk for 1 h. The nitrocellulose membranes were then
probed with specific primary antibodies against p-HER2 diluted 1:3000 in 5% milk for 15 h
at 4 °C. After incubation with primary antibody, the membranes were washed five times
with PBS and then incubated with secondary antibody to p-HER2 (anti-rabbit secondary
antibody) diluted 1:2000 in 5% milk with 0.001% Tween 20 for 1 h. The membranes were
washed five times with PBS, and proteins were visualized using the Super Signal enhanced
chemiluminescence kit (Pierce, Rockford, IL) [37]. The Kodak Gel Logic-1500 imaging
system (Carestream Molecular Imaging, New Haven, CT) was used to visualize the
luminescent proteins. All experiments were repeated at least three times. A representative
Western blot image was used for the final representation. The visualization of β-actin was
used to ensure equal sample loading in each lane. Total HER2 protein was detected using an
antibody to the HER2 extracellular domain (Abcam, Cambridge, MA).
5.5 Binding and cellular uptake of compound 5-7

NIH-PA Author Manuscript

Peptidomimetic compound 5-1 was conjugated with BODIPY dye to study its interaction
with HER2 protein. SKBR-3 cells were plated at 10,000 per well in a 96-well plate and
allowed to grow for 24 h. Compound 5-7 stock solution was diluted to 1 and 10 μM in
McCoy’s medium and added to the cells. Compound 5-7 was added to the 96-well plates
coated with SKBR3, and the plates were incubated at 37 °C. After time points of 0, 12, 24,
36, 48 and 72 h, the medium with compound 5-7 in the plates was removed, and the cells
were washed with PBS twice. The fluorescence of compound 5-7 was determined by
reading its fluorescence emission at 490 nm/530 nm (excitation/emission) using a BioTek
plate reader (Cary, NC). Similar experiments were conducted using chamber slides, and
images of cells with fluorescence were obtained using a confocal microscope. To the 8-well
plates coated with SKBR-3, compound 5-7 at a concentration of 0.4 μM was added, and the
plates were incubated at 37 °C. After time points of 24 and 48 h, the medium with
compound 5-7 in the plates was removed, and the cells were washed with PBS twice. The
cells were then fixed by adding 500 μL of ice-cold methanol and incubating the plate at −20
°C for 5 min. The methanol was discarded and immediately 500 μL of PBS was added twice
to the wells to prevent cell dehydration. Membrane and lyso trackers were diluted in serumfree medium and added to the wells treated with compound 5-7 as well as to the wells
without any treatment. The plates were incubated for 5 min (membrane tracker) and 30 min
(Lyso tracker) at 37 °C. After the incubation period, the wells were washed with PBS twice,
dried, and mounted with mounting medium for imaging [45]. Cells were viewed with a
confocal microscope (LSM 5 PASCAL). Images were taken at 40X under oil immersion
with argon and HeNe lasers. Images were analyzed with ZEN 2009 software.
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ACN

acetonitrile

BODIPY

4,4-difluoro-4-bora-3a,4a-diaza-s-indacene

BSA

bovine serum albumin

ECD

extracellular domain

6-Cl-HOBt

6-chloro-1-hydroxy-1H-benzotriazole

DMF

dimethylformamide

DCM

dichloromethane

DBU

1,8-diazabicyclo[5.4.0]undec-7-ene

EGFR

Epidermal growth factor receptor

Et3N

triethylamine

HATU

O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate

HER

human epidermal growth factor receptor

HRMS (ESI)

high-resolution mass spectrometry (electro-spray ionization)

LC/MS

liquid chromatography-mass spectrometry

MALDI-TOF

matrix-assisted laser desorption/ionization-time of flight

MeOH

methanol

PBS

phosphate-buffered saline

p-HER2

phosphorylated HER2

PLA

proximity ligation assay

PPI

protein-protein interactions

PyAOP

7-azabenzotriazol-1-yloxy) tripyrrolidinophosphonium
hexafluorophosphate

SDS

sodium dodecyl sulfate

SPSS

solid-phase peptide synthesis

TFA

trifluoroacetic acid
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•

A peptidomimetic targeting HER2 protein was conjugated with fluorescent label
BODIPY.

•

Cellular uptake of the conjugate was studied by confocal microscopy

•

Inhibition of protein-protein interaction was studied by proximity ligation assay

•

Designed compound inhibited HER2-HER3 interaction and inhibited
phosphorylation

•

Fluorescent conjugate designed is useful to study EGFR trafficking
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Fig. 1.

High resolution mass spectrum (HR-MS) of compound 5-7.
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Fig. 2.
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Inhibition of HER2-HER3 interaction evaluated by PLA assay (Duolink II). A) SKBR-3
cells without any treatment. Red dots indicate heterodimerization of HER2-HER3 proteins.
Notice the overexpression and dimerization of HER2 with HER3. B) SKBR-3 cells treated
with a control peptide. Notice that HER2-HER3 dimerization is not inhibited. C) and D), 0.5
μM and 0.8 μM compound 5-1 treated SKBR-3 cells. Compound 5-1 inhibited HER2HER3 dimerization indicated by the significant reduction in the number of red dots.
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Fig. 3.

Western blot analysis of phosphorylated HER2. BT-474, SKBR3 cells that overexpress
HER2 protein upon treatment with compound 5-1 (0.4 μM) showed decreased level of
phosphorylated HER2 over time. Total HER2 protein is also shown. A time dependent
inhibition of HER2 phosphorylation by compound 5-1 is observed in BT-474 and SKBR3.
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Fig. 4.

Time-dependent cellular binding and uptake of compound 5-7 at two concentrations.
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Fig. 5.
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Cellular localization of compound 5-7 monitored by membrane tracker. A) Membrane
tracker, B) compound 5-7, 24 hr, C) overlap 24 hrs. D) membrane tracker 48 hrs, compound
5-7, 48 hrs, F) Overlap.
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Fig. 6.
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Cellular localization of compound 5-7 monitored by Lyso tracker. A) Lyso tracker, B)
compound 5-7, 24 hr, C) overlap 24 hrs. D) Lyso tracker 48 hrs, compound 5-7, 48 hrs, F)
Overlap.
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Scheme 1.

Synthesis of 5-2 and 5-4 (tert-Butyl ester terminated conjugate).
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Scheme 2.

Synthesis of compound 5-7 using Wang resin.
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